Outpatient urticaria diagnosis codes have limited predictive value for same-day influenza vaccine adverse event detection

Journal of Clinical Epidemiology

Volumn 63, Issue 4, 2010, Pages 407-411

  Moore, Kristen M ^a   Duddy, April ^a   Lee, Grace M ^a   Velentgas, Priscilla ^a   Burwen, Dale R ^b   Platt, Richard ^a   Brown, Jeffrey S ^a  

^a HARVARD PILGRIM HEALTH CARE   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Claims databases; Diagnosis code; Influenza vaccine; Predictive value; Urticaria; Vaccine safety surveillance

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CARE PLANNING; HUMAN; INFANT; INFLUENZA; INFLUENZA VACCINATION; MALE; OUTPATIENT; PATIENT CODING; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKIN EXAMINATION; URTICARIA;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; CHILD, PRESCHOOL; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; INFANT; INFLUENZA VACCINES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; URTICARIA; YOUNG ADULT;

EID: 77249097301     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2009.08.002     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. Update: novel influenza A (H1N1) virus infections-worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep 58 (2009) 453-458
2. Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel Influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 58 (2009) 521-524
3. Birnbaum H.G., Cremieux P.Y., Greenberg P.E., LeLorier J., Ostrander J.A., and Venditti L. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 16 (1999) 1-8
4. Zingmond D.S., Wilber K.H., Maclean C.H., and Wenger N.S. Measuring the quality of care provided to community dwelling vulnerable elders dually enrolled in Medicare and Medicaid. Med Care 45 (2007) 931-938
5. Platt R., Davis R., Finkelstein J., Go A.S., Gurwitz J.H., Roblin D., et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf 10 (2001) 373-377
6. Udvarhelyi I.S., Gatsonis C., Epstein A.M., Pashos C.L., Newhouse J.P., and McNeil B.J. Acute myocardial infarction in the Medicare population: process of care and clinical outcomes. JAMA 268 (1992) 2530-2536
7. Collins A.J., Chen S.C., Gilbertson D.T., and Foley R.N. CKD surveillance using administrative data: impact on the health care system. Am J Kidney Dis 53 3 suppl 3 (2009) S27-S36
8. Schneeweiss S., and Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58 (2005) 323-337
9. Brown J.S., Kulldorff M., Chan K.A., Davis R.L., Graham D., Pettus P.T., et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf 16 (2007) 1275-1284
10. Davis R.L., Kolczak M., Lewis E., Nordin J., Goodman M., Shay D.K., et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology 16 (2005) 336-341
11. Lieu T.A., Kulldorff M., Davis R.L., Lewis E.M., Weintraub E., Yih K., et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 45 10 suppl 2 (2007) S89-S95
12. Burwen D.R., LaVoie L., Braun M.M., Houck P., and Ball R. Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiol Drug Saf 16 (2007) 753-761
13. Greene SK, Yin R, Kulldorff M, Lieu TA, Lewis EM, McClure DL, et al. Influenza vaccine safety: simulating real-time surveillance for adverse events in the Vaccine Safety Datalink project. Paper presented at: 48th Annual ICAAC/46th Annual IDSA Conference. Washington, DC. October 25, 2008.
14. Brown JS, Moore KM, Braun MM, Ziyadeh N, Chan KA, Lee GM, et al. Active influenza vaccine safety surveillance: potential within a healthcare claims environment. Med Care 2009 [ePub ahead of press].
15. Brewer T., and Colditz G.A. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 281 (1999) 824-829
16. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from VAERS. Pediatr Infect Dis J 23 (2004) 287-294
17. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Morb Mortal Wkly Rep 57 RR07 (2008) 1-60
18. Hambidge S.J., Glanz J.M., France E.K., McClure D., Xu S., Yamasaki K., et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 296 (2006) 1990-1997
19. France E.K., Glanz J.M., Xu S., Davis R.L., Black S.B., Shinefield H.R., et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med 158 (2004) 1031-1036
20. Tata L.J., West J., Harrison T., Farrington P., Smith C., and Hubbard R. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease?. Thorax 58 (2003) 835-839
21. Moore K, Brown JS for the HMO Research Network Center for Education and Research in Therapeutics. Variation in ICD-9 diagnosis coding of potential adverse events. 25th International Conference on Pharmacoepidemiology and Therapeutics Risk Management. August 2009; Providence, RI.